NCT05435677 - A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

IcoSema

One single dose of IcoSema administered subcutaneously, S.c. into the left thigh

DRUG

insulin icodec

One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh

DRUG

semaglutide

One single dose of semaglutide administered subcutaneously, S.c. into the left thigh

Trial Locations (1)

Peking University Third Hospital, Northern branch-Phase I, Beijing